<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01047488</url>
  </required_header>
  <id_info>
    <org_study_id>tcapgbcomb1</org_study_id>
    <secondary_id>2009-013642-80</secondary_id>
    <nct_id>NCT01047488</nct_id>
  </id_info>
  <brief_title>Imipramine and Pregabalin Combination in Painful Polyneuropathy</brief_title>
  <official_title>Randomised, Double-blind, Placebo-controlled Trial of the Effect of the Combination of Imipramine and Pregabalin for the Treatment of Painful Polyneuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nycomed</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Polyneuropathy of different etiologies is often associated with pain and the standard&#xD;
      treatment for this type of pain is gabapentinoids or antidepressants. The hypothesis of this&#xD;
      study is that the combination of the gabapentinoid pregabalin and the antidepressant&#xD;
      imipramine will provide better pain relief than the single compounds alone.&#xD;
&#xD;
      This is a randomized, placebo-controlled, double-blind, 4-way, cross-over trial of pregabalin&#xD;
      300 mg/day, imipramine 75 mg/day and their combination versus placebo. The study will include&#xD;
      60 patients and the treatment outcome will be pain intensity as measured by numeric rating&#xD;
      scales.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>February 2010</start_date>
  <completion_date type="Anticipated">March 2013</completion_date>
  <primary_completion_date type="Anticipated">March 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total pain intensity as measured by numeric rating scale 0-10 points.</measure>
    <time_frame>Median of ratings from last week of each treatment period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Verbal pain relief scale with 6 classes</measure>
    <time_frame>End of each treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specific pain symptom rated by numeric rating scales 0-10 points</measure>
    <time_frame>Median of ratings from last week of each treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rating of evoked pains symptoms (pressure, brush, repetitive pin-prick, cold) as measured by numeric rating scales 0-10 points</measure>
    <time_frame>End of each treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep disturbance as measured by numeric rating scale 0-10 points</measure>
    <time_frame>Median of ratings from last week of each treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Consumption of escape medication (number of tablets of paracetamol)</measure>
    <time_frame>Total consumption during last week of each treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life (SF-36)</measure>
    <time_frame>End of each treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Depression Inventory (MDI)</measure>
    <time_frame>End of each treament period</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Polyneuropathy</condition>
  <arm_group>
    <arm_group_label>Imipramine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Imipramine tablets and placebo capsules to pregabalin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pregabalin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pregabalin capsules and placebo tablets to imipramine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Imipramine plus pregabalin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Imipramine tablets and pregabalin capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets to imipramine and placebo capsules to pregabalin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imipramine</intervention_name>
    <description>Tablet 25 mg, 3 tablets evening (extensive metabolizers) or 1 tablet evening (poor metabolizers), daily, 5 weeks</description>
    <arm_group_label>Imipramine</arm_group_label>
    <other_name>Imipramin DAK</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin</intervention_name>
    <description>Capsule 75 mg, 2 capsules twice daily, daily, 5 weeks</description>
    <arm_group_label>Pregabalin</arm_group_label>
    <other_name>Lyrica</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imipramine, pregabalin</intervention_name>
    <description>Imipramine: tablet 25 mg, 3 tablets evening (extensive metabolizers) or 1 tablet evening (poor metabolizers), daily, 5 weeks Pregabalin: capsule 75 mg, 2 capsules twice daily, daily, 5 weeks</description>
    <arm_group_label>Imipramine plus pregabalin</arm_group_label>
    <other_name>Imipramin DAK</other_name>
    <other_name>Lyrica</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets to imipramine 25 mg, 3 or 1 tablet evening, daily, 5 weeks Placebo capsules to pregabalin 75 mg, 2 capsules daily, daily, 5 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 20 - 85 years.&#xD;
&#xD;
          -  Characteristic symptoms of polyneuropathy for at least 6 months.&#xD;
&#xD;
          -  Polyneuropathy diagnosis confirmed by typical clinical signs (distal sensory&#xD;
             disturbance/lack of distal deep tendon reflexes) and/or electrophysiological tests&#xD;
             and/or abnormal quantitative sensory tests.&#xD;
&#xD;
          -  Total pain intensity rating of at least 4 on a 0-10 points numeric rating scale.&#xD;
&#xD;
          -  Pain present at least 4 days a week.&#xD;
&#xD;
          -  For diabetics: diabetes diagnosis for at least 6 months and stable metabolic control&#xD;
             for at least 3 months.&#xD;
&#xD;
          -  For other secondary polyneuropathies: stable for at least 6 months.&#xD;
&#xD;
          -  For fertile females: adequate anticonceptive treatment.&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other cause of pain.&#xD;
&#xD;
          -  Contraindications against imipramine.&#xD;
&#xD;
          -  Allergic reactions towards imipramine or pregabalin.&#xD;
&#xD;
          -  Known adverse reactions during imipramine or pregabalin treatment.&#xD;
&#xD;
          -  Pregnancy.&#xD;
&#xD;
          -  Severe systemic disease.&#xD;
&#xD;
          -  Ongoing treatment with antidepressants, antipsychotics, anticonvulsants, opioids,&#xD;
             propranolol, kinidine, monoamine oxidase inhibitor.&#xD;
&#xD;
          -  Inability to follow study protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Søren H. Sindrup, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Neurology, Odense University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jakob V. Holbech, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurology, Odense University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Søren H. Sindrup, MD</last_name>
    <phone>+45 65412471</phone>
    <email>soeren.sindrup@ouh.regionsyddanmark.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jakob V. Holbech, MD</last_name>
    <email>Holbech@dadlnet.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Neurology, Aalborg Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>DK-9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <contact>
      <last_name>Flemming W. Bach, MD</last_name>
      <phone>+45 99321928</phone>
      <email>fwb@rn.dk</email>
    </contact>
    <investigator>
      <last_name>Flemming W. Bach, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>DK-5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <contact>
      <last_name>Søren H. Sindrup, MD</last_name>
      <phone>+45 65412471</phone>
      <email>soeren.sindrup@ouh.regionsyddanmark.dk</email>
    </contact>
    <contact_backup>
      <last_name>Jakob V. Holbech, MD</last_name>
      <email>Holbech@dadlnet.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Søren H. Sindrup, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jakob V. Holbech, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Aarhus University Hospital</name>
      <address>
        <city>Århus</city>
        <zip>DK-8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <contact>
      <last_name>Troels S. Jensen, MD</last_name>
      <phone>+45 89494137</phone>
      <email>tsjensen@ki.au.dk</email>
    </contact>
    <contact_backup>
      <last_name>Nanna Finnerup, MD</last_name>
      <email>finnerup@ki.au.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Troels S. Jensen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nanna Finnerup, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <study_first_submitted>January 12, 2010</study_first_submitted>
  <study_first_submitted_qc>January 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2010</study_first_posted>
  <last_update_submitted>January 12, 2010</last_update_submitted>
  <last_update_submitted_qc>January 12, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2010</last_update_posted>
  <responsible_party>
    <name_title>Søren Hein Sindrup</name_title>
    <organization>Department of Neurology, Odense University Hospital</organization>
  </responsible_party>
  <keyword>polyneuropathy</keyword>
  <keyword>neuropathic pain</keyword>
  <keyword>treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polyneuropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
    <mesh_term>Imipramine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

